{"filing":{"accession_number":"0001104659-26-097951","cik":"0001512762","ticker":"CHRS","company_name":"Coherus Oncology, Inc.","form":"8-K","filing_date":"2026-08-17","report_date":"2026-08-17","primary_document":"chrs-20260817x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1512762/000110465926097951/chrs-20260817x8k.htm"},"events":[{"id":28343,"run_id":25915,"accession_number":"0001104659-26-097951","anchor_item_number":"8.01","event_type":"dividend_distribution","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Coherus Oncology announced a special dividend distribution of contingent value rights (CVRs) to stockholders on a pro rata basis (one CVR per share), with a record date of September 30, 2026 and distribution on October 7, 2026. The CVRs entitle holders to receive net proceeds from the sale or monetization of the company's legacy biosimilar assets over a two-year term, representing a material capital allocation decision to unlock shareholder value while completing the company's transformation into a focused oncology company.","company_name":"Coherus Oncology, Inc.","ticker":"CHRS","filing_date":"2026-08-17","form":"8-K","submitted_at":null,"items":[{"id":30260,"accession_number":"0001104659-26-097951","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"dividend_distribution","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Coherus Oncology announced a special dividend of contingent value rights (CVRs) to be distributed pro rata to stockholders of record as of September 30, 2026, with distribution on October 7, 2026. The CVRs entitle holders to receive net proceeds from the sale or monetization of the company's legacy biosimilar assets. This is a material distribution to shareholders that would affect investor assessment of capital allocation and shareholder value realization.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-18T00:05:36.996621+00:00","company_name":"","ticker":null,"filing_date":""},{"id":30261,"accession_number":"0001104659-26-097951","item_number":"8.01","item_title":"Other Events.","event_type":"dividend_distribution","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Coherus Oncology announced a special dividend distribution of contingent value rights (CVRs) to stockholders on a pro rata basis, with one CVR per share of common stock held as of the Record Date (September 30, 2026). The CVRs entitle holders to receive potential future cash payments based on net proceeds from the sale or monetization of the company's Legacy BioSim Assets during a two-year term. This is a material capital distribution event that directly affects shareholder value and represents a strategic decision to unlock value from divested assets while completing the company's transformation into a focused oncology company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-18T00:05:36.996621+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30260,"accession_number":"0001104659-26-097951","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"dividend_distribution","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Coherus Oncology announced a special dividend of contingent value rights (CVRs) to be distributed pro rata to stockholders of record as of September 30, 2026, with distribution on October 7, 2026. The CVRs entitle holders to receive net proceeds from the sale or monetization of the company's legacy biosimilar assets. This is a material distribution to shareholders that would affect investor assessment of capital allocation and shareholder value realization.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-18T00:05:36.996621+00:00","company_name":"Coherus Oncology, Inc.","ticker":"CHRS","filing_date":"2026-08-17"},{"id":30261,"accession_number":"0001104659-26-097951","item_number":"8.01","item_title":"Other Events.","event_type":"dividend_distribution","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Coherus Oncology announced a special dividend distribution of contingent value rights (CVRs) to stockholders on a pro rata basis, with one CVR per share of common stock held as of the Record Date (September 30, 2026). The CVRs entitle holders to receive potential future cash payments based on net proceeds from the sale or monetization of the company's Legacy BioSim Assets during a two-year term. This is a material capital distribution event that directly affects shareholder value and represents a strategic decision to unlock value from divested assets while completing the company's transformation into a focused oncology company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-18T00:05:36.996621+00:00","company_name":"Coherus Oncology, Inc.","ticker":"CHRS","filing_date":"2026-08-17"}]}